Drug Type Peptide Conjugate Radionuclide, Therapeutic radiopharmaceuticals |
Synonyms [177Lu] labelled-minigastrin-analogue, Lutetium-177 minigastrin analogue, DEBIO 1124 + [1] |
Target |
Mechanism CCKB antagonists(Cholecystokinin B receptor antagonists), PET imaging(Positron-emission tomography enhancers) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Small Cell Lung Cancer | Phase 1 | CH | 17 Sep 2020 | |
Thyroid Cancer | Phase 1 | CH | 21 Mar 2020 | |
Gastro-Enteropancreatic Neuroendocrine Tumor | Phase 1 | CH | 01 Apr 2015 | |
Neuroendocrine carcinoma of thymus | Phase 1 | CH | 01 Apr 2015 | |
Respiratory Tract Neoplasms | Phase 1 | CH | 01 Apr 2015 | |
Thyroid Cancer, Medullary | Phase 1 | CH | 01 Apr 2015 |